Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation discusses starting hair loss treatments and concerns about side effects. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The user stopped taking 5 mg oral minoxidil after 15 days due to side effects and is experiencing hair shedding. They are now using topical minoxidil on temples and corners and have used oral finasteride for a year, seeking advice on hair regrowth and shedding duration.

The conversation discusses the potential long-term effects of stopping finasteride after extended use, with differing opinions on the existence and prevalence of post-finasteride syndrome (PFS). Some users report persistent side effects, while others argue that such effects are rare or unrelated to the medication.

Dutasteride 0.5 mg significantly reduces both scalp and hair follicle DHT, with a greater reduction in hair follicle DHT. The discussion questions which reduction is more important for androgenetic alopecia and diffuse thinning.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The user has been using oral minoxidil (5mg), finasteride (1mg), and biotin for 4 months with minimal progress in hair regrowth. Other users suggest patience, considering alternative treatments, and note that biotin may not significantly contribute unless there's a deficiency.

Regrowth is more likely if hair follicles are still alive, regardless of age, but younger individuals often see better results due to early intervention. Treatments like finasteride, minoxidil, and dermarolling can help, but results vary based on individual factors such as the presence of miniaturized hairs and the speed of treatment initiation.

The user experienced side effects like watery semen, erection problems, and decreased libido from finasteride, which resolved after stopping it. They are considering dutasteride mesotherapy as an alternative, as advised by their dermatologist, and are concerned about potential side effects.

Dutasteride and finasteride are not effectively stopping hair loss for some users, despite long-term use. Some are considering or using RU58841, pyrilutamide, and other treatments like microneedling, while also managing seborrheic dermatitis with diet and topical solutions.

Microneedling and tretinoin may enhance minoxidil absorption for hair loss, but evidence on their effectiveness is limited. Iron supplements and broccoli sprouts are suggested for enzyme activation, but their impact on hair is unclear.

A blood cancer survivor in remission since 2022 is experiencing thin and patchy hair after chemotherapy and is using Minoxidil without much success. They are seeking personal experiences and advice on hair transplants after cancer treatment.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

PP405 is being discussed for hair regrowth, with mixed opinions on its effectiveness and legitimacy. Some users report early signs of regrowth, while others are skeptical about its authenticity and results.

Monthly microneedling combined with low-dose topical dutasteride shows promising results for hair density and thickness with minimal side effects, especially in the frontal area. Despite its effectiveness, it is not widely discussed or used due to availability and cost concerns.

Tretinoin can cause non-telogen hair loss in some men by inducing catagen-like changes in hair follicles and through retinoid toxicity, especially when used with minoxidil. Some users report hair loss even when using retinoids on the face, while others experience benefits when combined with treatments like finasteride and minoxidil.

A user experienced significant hair regrowth after 3.5 months using topical minoxidil and weekly derma rolling. Others discussed enhancing results with finasteride, ketoconazole shampoo, and microneedling.

PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

Tretinoin and microneedling both enhance hair growth through different mechanisms, with microneedling being considered safe for long-term use. Optimal microneedling needle length varies, but 0.8 mm is suggested for hair growth, and a Dermastamp is recommended to avoid skin damage.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

New hair growth from minoxidil and finasteride is not reaching full length, possibly due to slow growth cycles. Users discuss dosing strategies for oral minoxidil to improve efficacy and minimize side effects, with advice against consuming topical minoxidil orally.

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.

The user is concerned about the quick prescription process for hair loss treatments like Minoxidil and Finasteride through HIMs, questioning the lack of a thorough evaluation. Another user reassures that such practices are common, emphasizing the effectiveness and low risk of these treatments, and suggests monitoring personal response to the medication.

The user is seeking recommendations for a knowledgeable dermatologist in the Denver/Boulder area to address male pattern baldness, as they are dissatisfied with their current treatment of topical finasteride and are considering switching to dutasteride. They feel their current doctor is not open to exploring different treatments that could improve hairline thickness.

Using hair fibers daily is generally fine, but it's important to choose a quality keratin-based product to avoid scalp irritation. The user combines hair fibers with a regimen of finasteride, minoxidil, microneedling, and ketoconazole.

A user on 1mg finasteride for a year has low estradiol levels but no significant symptoms, and others suggest monitoring without immediate concern. Some users discuss potential effects of low estrogen, like low libido, but the user reports no erectile dysfunction.

Finasteride can maintain hair for many years, but its effectiveness may decrease over time. Some switch to dutasteride or add minoxidil for better results, with side effects like libido changes and ED discussed.

Some users maintained hair gains after stopping microneedling while continuing minoxidil and finasteride, while others saw no improvement or experienced hair breakage. One user switched to oral minoxidil and continued finasteride and dutasteride after seeing no results from microneedling.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.